S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
OTCMKTS:TGAN

Transphorm (TGAN) Stock Price, News & Analysis

$4.79
-0.01 (-0.21%)
(As of 04/19/2024 ET)
Today's Range
$4.60
$4.82
50-Day Range
$4.79
$4.93
52-Week Range
$1.94
$4.96
Volume
382,906 shs
Average Volume
405,691 shs
Market Capitalization
$303.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.75
TGAN stock logo

About Transphorm Stock (OTCMKTS:TGAN)

Transphorm, Inc., a semiconductor company, develops, manufactures, and sells gallium nitride (GaN) semiconductor components for high voltage power conversion applications in Mainland China, Hong Kong, Taiwan, the United States, Japan, South Korea, India, and Europe. The company's products include GaN field effect transistors in various packages. Its GaN devices allows customers to design power systems creating functional value in various end products, including smartphone power adapters/fast-chargers, power supplies for datacenter servers/communication, industrial power converters, chargers/converters/inverters for electric vehicles, and other applications. The company offers its products through regional distributors and sales representatives. Transphorm, Inc. was founded in 2007 and is headquartered in Goleta, California.

TGAN Stock Price History

TGAN Stock News Headlines

Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Transphorm Stock: Maybe Not Fast Enough
Transphorm (TGAN) Receives a Buy from Benchmark Co.
Transphorm Announces Results of Rights Offering
See More Headlines
Receive TGAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Transphorm and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
4/20/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Industry
Semiconductor Equipment & Materials
Sub-Industry
N/A
Current Symbol
OTCMKTS:TGAN
Fax
N/A
Employees
128
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.75
High Stock Price Target
$8.00
Low Stock Price Target
$3.50
Potential Upside/Downside
+20.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-30,600,000.00
Net Margins
-189.65%
Pretax Margin
-189.65%

Debt

Sales & Book Value

Annual Sales
$18.76 million
Book Value
$0.33 per share

Miscellaneous

Free Float
60,188,000
Market Cap
$303.09 million
Optionable
Not Optionable
Beta
0.58
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Primit A. Parikh Ph.D. (Age 52)
    Co-Founder, President, CEO & Director
    Comp: $390.66k
  • Mr. Cameron McAulay (Age 48)
    Chief Financial Officer
    Comp: $350.66k
  • Dr. Umesh K. Mishra Ph.D. (Age 66)
    Chairman & CTO
    Comp: $180k
  • Mr. Philip Zuk
    Senior Vice President of Business Development & Marketing
  • Mr. Tushar Dhayagude
    Vice President of Worldwide Sales & FAE
  • Mr. Randy Berg
    Human Resources Leader
  • Mr. Sal Barlett
    Senior Vice President of Operations

TGAN Stock Analysis - Frequently Asked Questions

Should I buy or sell Transphorm stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Transphorm in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TGAN shares.
View TGAN analyst ratings
or view top-rated stocks.

What is Transphorm's stock price target for 2024?

2 Wall Street analysts have issued 1-year target prices for Transphorm's stock. Their TGAN share price targets range from $3.50 to $8.00. On average, they anticipate the company's stock price to reach $5.75 in the next twelve months. This suggests a possible upside of 20.0% from the stock's current price.
View analysts price targets for TGAN
or view top-rated stocks among Wall Street analysts.

How have TGAN shares performed in 2024?

Transphorm's stock was trading at $3.65 at the start of the year. Since then, TGAN stock has increased by 31.2% and is now trading at $4.79.
View the best growth stocks for 2024 here
.

How were Transphorm's earnings last quarter?

Transphorm, Inc. (OTCMKTS:TGAN) announced its earnings results on Tuesday, February, 20th. The company reported ($0.20) EPS for the quarter. The business had revenue of $4.67 million for the quarter. Transphorm had a negative trailing twelve-month return on equity of 114.30% and a negative net margin of 189.65%.

How do I buy shares of Transphorm?

Shares of TGAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:TGAN) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners